Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells

JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929.

Abstract

Similar to tumor-initiating cells (TICs), minimal residual disease (MRD) is capable of reinitiating tumors and causing recurrence. However, the molecular characteristics of solid tumor MRD cells and drivers of their survival have remained elusive. Here we performed dense multiregion transcriptomics analysis of paired biopsies from 17 ovarian cancer patients before and after chemotherapy. We reveal that while MRD cells share important molecular signatures with TICs, they are also characterized by an adipocyte-like gene expression signature and a portion of them had undergone epithelial-mesenchymal transition (EMT). In a cell culture MRD model, MRD-mimic cells showed the same phenotype and were dependent on fatty acid oxidation (FAO) for survival and resistance to cytotoxic agents. These findings identify EMT and FAO as attractive targets to eradicate MRD in ovarian cancer and make a compelling case for the further testing of FAO inhibitors in treating MRD.

Keywords: Fatty acid oxidation; Obstetrics/gynecology; Oncology.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / metabolism*
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma, Ovarian Epithelial / drug therapy
  • Carcinoma, Ovarian Epithelial / genetics*
  • Carcinoma, Ovarian Epithelial / metabolism
  • Cell Line, Tumor
  • Cytoreduction Surgical Procedures
  • Epithelial-Mesenchymal Transition / genetics*
  • Fatty Acids / metabolism
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm, Residual / genetics*
  • Neoplasm, Residual / metabolism
  • Neoplastic Stem Cells / metabolism*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / metabolism
  • Oxidation-Reduction
  • Paclitaxel / administration & dosage
  • Transcriptome

Substances

  • Fatty Acids
  • Carboplatin
  • Paclitaxel